These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19555718)

  • 21. Recent contributions of in vitro models to our understanding of hepatitis C virus life cycle.
    Régeard M; Lepère C; Trotard M; Gripon P; Le Seyec J
    FEBS J; 2007 Sep; 274(18):4705-18. PubMed ID: 17824957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mathematical modeling of HCV infection and treatment.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A highly sensitive and reproducible HCV RNA hybridization method valuable for antiviral drug discovery.
    Zhao Y; Sanchez A; Nie X; Liu D; Hou X; Fabrycki J; Phadke A; Deshpande M; Huang M; Yang W
    J Virol Methods; 2008 Jul; 151(1):154-7. PubMed ID: 18466983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new living cell-based assay system for monitoring genome-length hepatitis C virus RNA replication.
    Dansako H; Ikeda M; Abe K; Mori K; Takemoto K; Ariumi Y; Kato N
    Virus Res; 2008 Oct; 137(1):72-9. PubMed ID: 18602954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening of small-molecule compounds as inhibitors of HCV entry.
    Yang JP; Zhou D; Wong-Staal F
    Methods Mol Biol; 2009; 510():295-304. PubMed ID: 19009270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.
    Ueda Y; Mori K; Ariumi Y; Ikeda M; Kato N
    Biochem Biophys Res Commun; 2011 Jun; 409(4):663-8. PubMed ID: 21620801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entry of pseudotyped hepatitis C virus into primary human hepatocytes depends on the scavenger class B type I receptor.
    Régeard M; Trotard M; Lepère C; Gripon P; Le Seyec J
    J Viral Hepat; 2008 Dec; 15(12):865-70. PubMed ID: 19087225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of human hepatocyte-like cells derived from induced pluripotent stem cells as a model for hepatocytes in hepatitis C virus infection.
    Yoshida T; Takayama K; Kondoh M; Sakurai F; Tani H; Sakamoto N; Matsuura Y; Mizuguchi H; Yagi K
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):119-24. PubMed ID: 22093821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
    Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
    Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.
    Gottwein JM; Bukh J
    Adv Virus Res; 2008; 71():51-133. PubMed ID: 18585527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro replicative properties of replicons constructed using sequence variants of the hepatitis C virus strain AD78 that caused a single-source outbreak of hepatitis C.
    Oniangue-Ndza C; Aus dem Siepen M; Lohmann V; Wiese M; Viazov S; Roggendorf M
    Virus Res; 2009 Jun; 142(1-2):1-9. PubMed ID: 19103237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cell-based bicistronic lentiviral reporter system for identification of inhibitors of the hepatitis C virus internal ribosome entry site.
    Lourenço S; Boni S; Furling D; Cosset FL; Cahour A
    J Virol Methods; 2009 Jun; 158(1-2):152-9. PubMed ID: 19428584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell entry of hepatitis C virus.
    Bartosch B; Cosset FL
    Virology; 2006 Apr; 348(1):1-12. PubMed ID: 16455127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A small-molecule probe for hepatitis C virus replication that blocks protein folding.
    Rakic B; Clarke J; Tremblay TL; Taylor J; Schreiber K; Nelson KM; Abrams SR; Pezacki JP
    Chem Biol; 2006 Oct; 13(10):1051-60. PubMed ID: 17052609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arrest all accessories--inhibition of hepatitis C virus by compounds that target host factors.
    von Hahn T; Ciesek S; Manns MP
    Discov Med; 2011 Sep; 12(64):237-44. PubMed ID: 21955851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents.
    Buckwold VE; Beer BE; Donis RO
    Antiviral Res; 2003 Sep; 60(1):1-15. PubMed ID: 14516916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approaches for the development of antiviral compounds: the case of hepatitis C virus.
    Schinazi RF; Coats SJ; Bassit LC; Lennerstrand J; Nettles JH; Hurwitz SJ
    Handb Exp Pharmacol; 2009; (189):25-51. PubMed ID: 19048196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospects for hepatitis C vaccine.
    Bhopale GM; Nanda RK
    Acta Virol; 2004; 48(4):215-21. PubMed ID: 15745044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of subgenomic hepatitis C virus replication by 5'-O-masked analogues of 6-chloropurine-2'-deoxyriboside.
    Ikejiri M; Ohshima T; Kato K; Toyama M; Murata T; Shimotohno K; Maruyama T
    Nucleic Acids Symp Ser (Oxf); 2007; (51):439-40. PubMed ID: 18029775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.
    Koutsoudakis G; Romero-Brey I; Berger C; Pérez-Vilaró G; Monteiro Perin P; Vondran FW; Kalesse M; Harmrolfs K; Müller R; Martinez JP; Pietschmann T; Bartenschlager R; Brönstrup M; Meyerhans A; Díez J
    J Hepatol; 2015 Oct; 63(4):813-21. PubMed ID: 26070407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.